Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus

@article{Briones2006ExenatideAG,
  title={Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus},
  author={M. Briones and M. Bajaj},
  journal={Expert Opinion on Pharmacotherapy},
  year={2006},
  volume={7},
  pages={1055 - 1064}
}
  • M. Briones, M. Bajaj
  • Published 2006
  • Medicine
  • Expert Opinion on Pharmacotherapy
    • Exenatide is a glucagon-like peptide 1 receptor agonist, which has recently received FDA approval in the US for the treatment of Type 2 diabetes. Exenatide is an incretin mimetic that improves glycaemic control in patients with diabetes through acute mechanisms, such as glucose-dependent stimulation of insulin secretion, suppression of inappropriate glucagon secretion and slowing of gastric emptying, as well as chronic mechanisms that include enhancement of β-cell mass in rodent studies and… CONTINUE READING
    View on Taylor & Francis
    ncbi.nlm.nih.gov
    55 Citations
    Highly Influencial Citations
    3
    Background Citations
    19
    Methods Citations
    2
    55 Citations
    Citation Type

    Citation Type

    DPP-4 Inhibition and the Path to Clinical Proof
    • 14
    • PDF
    The role of incretin on diabetes mellitus.
    • 6
    A novel GLP-1 analog exhibits potent utility in the treatment of type 2 diabetes with an extended half-life and efficient glucose clearance in vivo
    • 7
    Novel Modified GLP-1 Derivatives with Prolonged Glucose-Lowering Ability In Vivo
    A New Horizon: Oxytocin as a Novel Therapeutic Option for Obesity and Diabetes.
    • 28
    Pharmacokinetics and Preliminary Pharmacodynamics of Single- and Multiple-dose Lyophilized Recombinant Glucagon-like Peptide-1 Receptor Agonist (rE-4) in Chinese Patients with Type 2 Diabetes Mellitus
    • 1
    • Highly Influenced
    Design, synthesis, and biological activity of novel dicoumarol glucagon-like peptide 1 conjugates.
    • 46
    • PDF
    New Drugs for Type 2 Diabetes Mellitus
    • 37
    Disulfide bond prolongs the half-life of therapeutic peptide-GLP-1
    • 16
    Application of novel peptide (Pp1) improving the half-life of exendin-4 in vivo
    • 6

    References

    SHOWING 1-10 OF 90 REFERENCES
    Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes
    • 427
    Enhancing incretin action for the treatment of type 2 diabetes.
    • 582
    • PDF
    Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes.
    • 89
    • PDF
    The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes.
    • 235
    • PDF
    Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes.
    • 559
    • Highly Influential
    • PDF
    Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes.
    • 364
    • Highly Influential
    • PDF
    Therapy of type 2 diabetes mellitus based on the actions of glucagon‐like peptide‐1
    • J. Holst
    • Medicine
    • Diabetes/metabolism research and reviews
    • 2002
    • 145
    Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2.
    • 448
    • Highly Influential
    Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus.
    • 821
    Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers.
    • 434
    • PDF